- About
- Treatments
FACIAL
INJECTABLESSKIN
TREATMENTSBODY
TREATMENTS - Locations
- Pricing
- Shop
- Aftercare
- Contact
Menu
LUMIGAN® is the brand name for bimatoprost, a medication already FDA approved for the treatment of glaucoma. LATISSE® is FDA approved for the treatment of hypotrichosis of the eyelashes by making them grow longer, thicker and darker, it is a version of the drug Bimatoprost and it’s brand name is LUMIGAN®. Hypotrichosis is a medical term for short or missing lashes, It is frequently seen in men and women as they approach middle age. LUMIGAN® is believed to affect the growth (anagen) phase of the eyelash hair cycle by increasing the length of the growth phase and increasing the number of hairs along the eyelid margin.
The onset of action is gradual with most users seeing a significant improvement in the length and number of lashes by 2 months. If LUMIGAN® is discontinued the eyelashes and eyelids will return to their previous appearance over several weeks to months.
There are no FDA approved alternatives.
The following side effects are the most frequently reported, but occur in less than 4% of users (i.e. 4 out of 100 users)
LUMIGAN® solution is a growth treatment for lashes. LUMIGAN® solution is a once-nightly treatment you apply topically to the base of your upper eyelashes. Then, gradually, the results come in. You may start to see more length in as little as 4 weeks and you should achieve full growth in 16 weeks. It’s not an illusion of growth. It’s real lash growth. LUMIGAN® makes lash growth possible because of its active ingredient: bimatoprost.
Although the precise mechanism of action is unknown, LUMIGAN® is believed to affect the growth (anagen) phase of the eyelash hair cycle in two ways: first, it increases the length of this phase, and second, it increases the number of hairs in this growth phase.
LUMIGAN® was created by Allergan, a pharmaceutical leader with 60 years of eye care expertise.In 2001, Allergan developed a medicated eye drop to treat elevated intraocular pressure. Many patients using this medication also began to grow longer, fuller and darker lashes as a side effect. This led Allergan to study the medication’s active ingredient, bimatoprost, specifically for growing lashes, Latisse. Lumigan is a genereric version of Latisse but is prescribed outside of its licensed indications.
The most common side effect after using LUMIGAN® is an itching sensation in the eyes and/or eye redness, which was reported in approximately 4% of clinical trial patients. LUMIGAN® solution may cause other less common side effects which typically occur close to where LUMIGAN® is applied. These include skin darkening, eye irritation, dryness of the eyes and redness of the eyelids.
If you develop a new ocular condition (e.g., trauma or infection), experience a sudden decrease in vision, have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, you should immediately seek your doctor’s advice concerning the continued use of LUMIGAN® solution.
LUMIGAN® solution is intended for use on the skin of the upper eyelid margins at the base of the eyelashes. Refer to the illustration above in ‘How to Apply’. DO NOT APPLY to the lower lid. If you have a history of abnormal elevated intraocular pressure or glaucoma, you should only use LUMIGAN® under the close supervision of your doctor.
LUMIGAN® solution use may cause darkening of the eyelid skin which may be reversible. LUMIGAN® use may cause increased brown iris pigmentation of the coloured part of the eye which is likely to be permanent. While very infrequent, increased iris pigmentation has occurred when LUMIGAN® was administered.
It is possible for hair growth to occur in other areas of your skin that LUMIGAN® frequently touches. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent material to reduce the chance of this happening. It is possible for a difference in eyelash length, thickness, fullness, pigmentation (darkness), number of eyelash hairs and/or direction of eyelash growth to occur between eyes (e.g., results may vary for each eye). These differences, should they occur, will usually go away if you stop using LUMIGAN®
I understand that though complications are uncommon, they do sometimes occur. It is possible that side effects not described may occur and indeed that a complication not previously reported may occur for the first time. I understand if I suffer any adverse reactions that are not expected, or concern me, I must contact my practitioner, and book a review appointment. MD Medical Aesthetics Ltd cannot take responsibility for complications or results that have not been reported, assessed, documented and managed in a timely manner. Whilst I have been advised of the probable result, this cannot be interpreted as a guarantee. Results vary from one individual to another.
I confirm that the medical health history form has been completed truthfully and I am fully aware that withholding medical information, including history of previous treatment, may be detrimental to the safe and optimal outcome of any treatment administered. If there are any changes in my medical history, I must inform the practitioner.
I confirm that I have been provided with verbal and written information about this treatment which includes aftercare and follow up advice and I agree to follow the aftercare advice and understand this reduces risk of adverse reactions and helps ensure optimum results.
I understand information about me will be treated as confidential and access to it restricted in accordance with the Data Protection Act, unless specific permissions given.
By consenting to treatment you accept the clinic terms and conditions as outlined:
Copyright © 2024. All rights reserved.
